Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety study of amifampridine phosphate in ambulatory patients with SMA type 3
2018-000160-28Phase 2Terminated
- Sponsor
- Catalyst Pharmaceuticals
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amifampridine in Spinal muscular atrophy type 3 (SMA3), sponsored by Catalyst Pharmaceuticals. Primary endpoint: Long-term safety and tolerability. Started May 2021; status: terminated.
02
Drugs
amifampridine
03
Conditions
Spinal muscular atrophy type 3 (SMA3)
Beyond the preview
Go deeper on 2018-000160-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000160-28.